SS
CDTX

SBI Securities’s Cidara Therapeutics CDTX Stock Holding History

SBI Securities’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-9
Closed -$438 – 4205
2025
Q2 		$438 Sell
9
-11
-55% -$264 ﹤0.01% 3020
2025
Q1 		$431 Hold
20
– – ﹤0.01% 2921
2024
Q4 		$538 Buy
+20
New +$325 ﹤0.01% 2866

Other funds holding CDTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

SBI Securities's CDTX Position: Q3 2025 in Review

SBI Securities sold out of Cidara Therapeutics (CDTX) in Q3 2025, closing a stake of 9 shares — an estimated $438 sold.

SBI Securities first reported a position in CDTX in Q4 2024 and held it in 3 quarters. The position peaked at $538 in Q4 2024. 173 funds tracked by Wall St. Rank hold CDTX as of Q3 2025.

  • SBI Securities reported no remaining Cidara Therapeutics position as of Q3 2025 after selling out during the quarter.
  • SBI Securities sold 9 Cidara Therapeutics shares in Q3 2025, an estimated $438.
  • SBI Securities first reported a position in Cidara Therapeutics in Q4 2024 and held it in 3 quarters.
  • SBI Securities's Cidara Therapeutics position peaked at $538 in Q4 2024.
  • 173 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q3 2025.

Based on SBI Securities's 13F filing for Q3 2025, filed 5 Nov 2025.